Arbios to start SEPET trial
Arbios Systems Inc. has received conditional approval from the FDA of an Investigational Device Exemption (”IDE”) to commence the pivotal clinical trial for SEPET(TM). SEPET is an extracorporeal (outside the body) device that assists the liver to purify blood of chronically ill patients suffering from acute liver failure. Arbios is still required by the FDA to furnish some information related to the device before it can receive final approval.
- Mylan receives FDA nod for generic Plendil
- Merge Healthcare Releases Updated DICOM Toolkit
- Barr Pharma receives FDA nod for generic Mirapex
- FDA approves sealant to control bleeding
